Sirolimus: Clinical Trials

374 trials of Sirolimus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

188 completed, 49 recruiting, 48 terminated, 34 active not recruiting. 374 Phase 2, 106 Phase 1, 26 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2374Completed 188, Recruiting 49, Terminated 48, Active not recruiting 34, Unknown 22, Not yet recruiting 15, Withdrawn 14, Enrolling by invitation 3, Suspended 1
Phase 1106Completed 45, Recruiting 17, Terminated 12, Active not recruiting 11, Unknown 8, Withdrawn 7, Not yet recruiting 4, Enrolling by invitation 1, Suspended 1
Phase 326Completed 9, Recruiting 7, Terminated 4, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1

Follow Sirolimus: new trials by email Literature Review of Sirolimus trials Research Report on Sirolimus

Trials (filtered) newest first · largest first

All 374 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption
Baricitinib 2 MG, Sirolimus 2 MG, Placebo of baricitinib 2 MG - HIV-1-infection
Phase 2Not yet recruitingANRS, Emerging Infectious Diseases1912027-05-012026-10-19
Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage
Sirolimus (Rapamune®) - Post-hemorrhagic Hydrocephalus (PHH)
Phase 1 / Phase 2Not yet recruitingMassachusetts General Hospital152027-01-012026-06-25
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC)
Phase 2Not yet recruitingWashington University School of Medicine222026-11-302026-10-15
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)542026-11-192026-11-16
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia
Phase 2RecruitingCity of Hope Medical Center352026-11-052026-10-08
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4
Phase 1 / Phase 2Not yet recruitingCedars-Sinai Medical Center602026-11-012026-09-16
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus - Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum
Phase 2Not yet recruitingCase Comprehensive Cancer Center202026-11-012026-09-24
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin
Phase 1 / Phase 2RecruitingUmoja Biopharma2742026-11-012026-11-10
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer
Phase 1 / Phase 2Not yet recruitingUniversity Hospital, Strasbourg, France892026-10-012026-10-01
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
Sirolimus, Ruxolitinib, MMF - Acute Leukemia, Myelodysplastic Syndromes
Phase 1 / Phase 2Not yet recruitingPeking University People's Hospital402026-10-012026-09-09
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease
Phase 2RecruitingSt. Jude Children's Research Hospital452026-09-102026-11-12
Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis
Rapamycin - Familial Adenomatous Polyposis
Phase 2Not yet recruitingUniversity Hospital, Toulouse252026-09-012026-05-08
A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma
Sirolimus for injection (Albumin-bound) - Epithelioid Hemangioendothelioma
Phase 2Not yet recruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.402026-08-012026-07-06
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Domatinostat, Sirolimus - Sarcoma, Osteosarcoma
Phase 1 / Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute742026-07-152026-09-03
Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP
Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon
Phase 2 / Phase 3RecruitingYi Ji762026-06-162026-06-18
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia
Phase 2 / Phase 3RecruitingChinese SLE Treatment And Research Group1642026-06-072026-06-18
Vertebrobasilar Dolichoectasia Treatment With Sirolimus
Sirolimus - Vertebrobasilar Dolichoectasia
Phase 2Not yet recruitingHuashan Hospital122026-06-012026-06-08
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease
Phase 2RecruitingIncyte Corporation602026-05-202026-11-13
MTOR Inhibitors in Older Adults
Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet - Aging
Phase 1 / Phase 2RecruitingUniversity of Texas Southwestern Medical Center602026-05-112026-06-25
Vaccination Response Modulation With a Targeted Rapamycin Protocol Study
Sirolimus (RAPAMUNE), Influenza vaccine (Sequiris Fluad Quad), RSV vaccine (Pfizer Abrysvo) - Vaccine Immune Response, Haemodialysis Patients
Phase 2Not yet recruitingCentral Adelaide Local Health Network Incorporated602026-05-012026-05-14

Showing 20 of 374. Sign in to see all of them.

Conditions studied

Graft vs Host Disease (38)  ·  Myelodysplastic Syndromes (26)  ·  Leukemia, Myeloid, Acute (25)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (24)  ·  Lymphoma, Non-Hodgkin (22)  ·  Anemia, Sickle Cell (19)  ·  Hodgkin Disease (18)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (18)  ·  Multiple Myeloma (18)  ·  Leukemia (15)  ·  Hematologic Neoplasms (14)  ·  Lymphoma, Mantle-Cell (14)  ·  Sarcoma (14)  ·  Diabetes Mellitus, Type 1 (13)  ·  Lymphoma, Large B-Cell, Diffuse (13)

Sponsors

National Cancer Institute (NCI) (53)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (18)  ·  Fred Hutchinson Cancer Center (11)  ·  Dana-Farber Cancer Institute (9)  ·  National Heart, Lung, and Blood Institute (NHLBI) (8)  ·  City of Hope Medical Center (6)  ·  H. Lee Moffitt Cancer Center and Research Institute (6)  ·  National Eye Institute (NEI) (6)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (5)  ·  Masonic Cancer Center, University of Minnesota (5)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5)  ·  Peking University People's Hospital (5)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5)  ·  Stanford University (5)  ·  West China Hospital (5)

Countries

United States (262)  ·  China (26)  ·  Canada (19)  ·  Italy (14)  ·  France (11)  ·  Spain (10)  ·  Germany (7)  ·  United Kingdom (6)  ·  Australia (5)  ·  Belgium (5)  ·  South Korea (5)  ·  Sweden (4)  ·  Denmark (3)  ·  Netherlands (3)  ·  New Zealand (3)

Top investigators

Elizabeth M Kang, M.D. (5)  ·  Christopher G Kanakry, M.D. (4)  ·  Joel Naor, MD (4)  ·  Damiano Rondelli, MD (3)  ·  Laura Johnston (3)  ·  Lorenzo Piemonti, MD (3)  ·  Yi Ji, MD, PhD (3)  ·  AeRang Kim, MD, PhD (2)  ·  Aldo T Iacono, MD (2)  ·  Arun Rajan, M.D. (2)  ·  Brenda Sandmaier (2)  ·  Brigitte Widemann, MD (2)  ·  Corey Cutler, MD, MPH (2)  ·  Courtney F Joseph, M.D. (2)  ·  Edwin P. Alyea, MD (2)

Results publications

PMID 36240296, PMID 35030255, PMID 42133908, PMID 28486787, PMID 31489702, PMID 32014025, PMID 39356039, PMID 22871490, PMID 30270358, PMID 33580918, PMID 34273457, PMID 34524406, PMID 35254001, PMID 39831682, PMID 40010689, PMID 40107509, PMID 41114938, PMID 41871072, PMID 12176626, PMID 12176628, PMID 15233820, PMID 15257060, PMID 16407509, PMID 17005949, PMID 17090654, PMID 17510057, PMID 18184959, PMID 18215105, PMID 18416737, PMID 18997171, PMID 19127265, PMID 19167681, PMID 19192962, PMID 19208097, PMID 19238149, PMID 19539216, PMID 19562254, PMID 19663893, PMID 19710204, PMID 19950289, PMID 20007560, PMID 20107229, PMID 20501622, PMID 20664591, PMID 20837940, PMID 20847709, PMID 21084848, PMID 21135251, PMID 21314851, PMID 21403127

NIH funding

P30CA015704 (8), U10CA025224 (6), N01CM00071 (5), N01CM62201 (5), U10CA027469 (5), N01CM00038 (4), P30CA006973 (4), P30CA014599 (4), P30CA033572 (4), U10CA021115 (4), 2018 (3), 2025 (3), N01CM00099 (3), N01CM62202 (3), N01CM62207 (3)